<DOC>
	<DOCNO>NCT00986674</DOCNO>
	<brief_summary>This randomized phase II trial study well give carboplatin paclitaxel together cetuximab and/or cixutumumab ( IMC-A12 ) work treat patient stage IIIB stage IV non-small cell lung cancer . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab cixutumumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving chemotherapy together monoclonal antibody therapy may kill tumor cell . It yet know whether carboplatin paclitaxel effective give cetuximab and/or cixutumumab treat non-small cell lung cancer .</brief_summary>
	<brief_title>Carboplatin Paclitaxel Combined With Cetuximab and/or IMC-A12 Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate progression-free survival patient non-small cell lung cancer ( NSCLC ) randomize carboplatin plus paclitaxel plus cetuximab carboplatin plus paclitaxel plus cixutumumab ( IMC-A12 ) carboplatin plus paclitaxel plus cetuximab plus cixutumumab . SECONDARY OBJECTIVES : I . To evaluate response rate , disease control rate ( complete response plus partial response plus stable disease ) , toxicities arm . II . To evaluate epidermal growth factor receptor ( EGFR ) Immunohistochemistry ( IHC ) , mutation , gene copy number , Insulin-like growth factor 1 receptor ( IGF-1R ) Insulin-like growth factor 2 receptor ( IGF-2R ) expression ( phosphorylated unphosphorylated state ) , expression p-AKT ( ie , Protein Kinase B ) IHC , k-ras mutation . III . Plasma-based biomarkers evaluate total free insulin-like growth factor 1 2 , IGF-growth factor bind protein 3 ( IGFBP3 ) circulating level epidermal growth factor ( EGF ) Transforming growth factor ( TGF ) alpha . IV . To evaluate overall survival three arm . OUTLINE : This multicenter study . Patients stratify accord gender histology ( squamous cell v non-squamous cell ) . Patients randomize 1 3 treatment arm . ARM I : Patients receive carboplatin intravenously ( IV ) 15-30 minute paclitaxel IV 3 hour day 1 22 cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 , 29 , 36 . Treatment repeat every 42 day 2 course . Patients stable respond disease 2 course proceed maintenance therapy cetuximab alone day 1 , 8 , 15 , 22 , 29 , 36 . Treatment cetuximab repeat every 42 day absence disease progression unacceptable toxicity . ARM II : Patients receive carboplatin paclitaxel arm I . Patients also receive cixutumumab IV 1 hour day 1 , 15 , 29 . Treatment repeat every 42 day 2 course . Patients stable respond disease 2 course proceed maintenance therapy cixutumumab alone day 1 , 15 , 29 . Treatment cixutumumab repeat every 42 day absence disease progression unacceptable toxicity . ARM III : Patients receive carboplatin , paclitaxel , cetuximab arm I . Patients also receive cixutumumab arm II . Treatment repeat every 42 day 2 course . Patients stable respond disease 2 course proceed maintenance therapy cetuximab arm I cixutumumab arm II . Tumor tissue sample collect baseline analysis EGFR expression IHC , mutation , gene copy number ; IGF-1R IGF-2R expression ( phosphorylated unphosphorylated state ) ; p-AKT expression IHC ; k-ras mutation . Blood , serum , plasma sample collect periodically biomarker analysis . After completion study treatment , patient follow every 3 month 2 year every 6 month 1 year . PROJECTED ACCRUAL : 200 patient</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IIIB disease T4 , NX nodule ipsilateral lung lobe allow provided patient candidate combine chemotherapy radiotherapy Stage IV disease ( include M1a M1b ) Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criteria Ineligible refuse treatment bevacizumab No untreated symptomatic central nervous system ( CNS ) metastases Patients history CNS metastases definitively treat , stable , control eligible provide follow criterion meet : Definitive therapy ( surgery and/or radiotherapy ) administer Not plan undergo additional treatment brain metastasis Clinically stable Off corticosteroid stable dose corticosteroid ≥ 14 day study entry ECOG performance status 01 Leukocytes &gt; 3,000/mm^3 Absolute neutrophil count ( ANC ) &gt; 1,500/mm^3 Hemoglobin &gt; 9 g/dL Platelet count &gt; 100,000/mm^3 Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Aspartate Aminotransferase ( AST ) &lt; 3 time ULN ( &lt; 5 time ULN elevation due liver metastasis ) Creatinine &lt; 1.5 time ULN OR creatinine clearance &gt; 60 mL/min Fasting serum glucose &lt; 120 mg/dL Partial thromboplastin time ( PTT ) ≤ 1.2 time ULN international normalize ratio ( INR ) ≤ 1.5 ( unless patient anticoagulation therapy ) Negative pregnancy test Fertile patient must use effective contraception 3 month last dose cixutumumab No poorly control diabetes mellitus Patients history diabetes mellitus eligible provide blood glucose within normal range stable dietary therapeutic regimen condition No prior concurrent malignancy , except follow : Curatively treated malignancy know active disease ≥ 3 year AND consider low risk recurrence treat physician Adequately treated nonmelanoma skin cancer lentigo maligna evidence disease Adequately treat cervical carcinoma situ evidence disease Prostatic intraepithelial neoplasia evidence prostate cancer Concurrent therapeutic anticoagulation allow provided bleeding patient stable dose anticoagulation therapy ( e.g. , Warfarin INR 23 ) &gt; 2 week prior study entry At least 21 day since prior radiotherapy More 4 week since prior major surgery hormonal therapy ( hormone replacement therapy ) recover More 1 year since prior neoadjuvant adjuvant chemotherapy Exclusion criterion : Small cell lung cancer mix small cell NSCLC History allergic reaction attribute compound similar chemical biological composition cixutumumab History medical psychiatric condition , addictive disorder , laboratory abnormality , opinion investigator , may increase risk associate study participation study treatment may interfere conduct study interpretation study result Prior agent target EGFR Insulinlike growth factor ( IGFR ) pathways Prior therapy advance NSCLC , except surgery and/or radiotherapy Prior systemic therapy , include bevacizumab advance stage NSCLC Pregnant nurse Peripheral neuropathy &gt; grade 1 per Common Terminology Criteria Adverse Event ( CTCAE ) v 4.0 History suspect interstitial pneumonitis pulmonary fibrosis image Significant uncontrolled cardiac disease within past 6 month , include follow : Uncontrolled hypertension ( BP &gt; 150/100 mm Hg ) Unstable angina Recent myocardial infarction Uncontrolled congestive heart failure Cardiomyopathy decrease ejection fraction Arterial thrombosis , pulmonary embolus , deep vein thrombosis , hemorrhagic disorder within past 28 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Advanced Non-small Cell Lung Cancer</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>IMC-A12</keyword>
</DOC>